PARP1 and neoplasm: Earlier reports indicate the involvement of PARP1 hyperactivation in cisplatin resistance in other tumor types.To determine the effect of olaparib on PARP1 activity, CC cells were treated with cisplatin along with two different concentrations (5 μM and 10 μM) of olaparib.